Collaboration to provide affordable hepatitis C treatment in Latin America

6 March 2018

A new collaboration between pharmaceutical companies and non-profit organizations will manufacture and supply a new, more affordable, hepatitis C treatment regimen in Latin America.

An estimated 3.5 million people live with this viral disease in Latin America including around 325,000 in Argentina, with high treatment prices one of the many barriers to access for life-saving care.

Under the terms of the collaboration announced at the 18th International Congress on Infectious Diseases (ICID), Buenos Aires, Egyptian drugmaker Pharco Pharmaceuticals will supply the active pharmaceutical ingredients for sofosbuvir and drug candidate ravidasvir. Insud Pharma and Argentinian R&D company Laboratorio Elea Phoenix will register, manufacture, and distribute ravidasvir and sofosbuvir in Latin America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK